We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

New Class of Antibodies Raises Hope of Dengue Fever Vaccine

New Class of Antibodies Raises Hope of Dengue Fever Vaccine

New Class of Antibodies Raises Hope of Dengue Fever Vaccine

New Class of Antibodies Raises Hope of Dengue Fever Vaccine

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New Class of Antibodies Raises Hope of Dengue Fever Vaccine"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dengue fever cases have risen dramatically in recent decades as the disease has spread to new areas. An estimated 390 million infections occur each year, with around 40 per cent of the world’s population living in areas at risk. In most cases it causes flu-like illness, but in some patients it develops into dengue haemorrhagic fever, which can lead to shock, haemorrhage and death.

Studying blood from people infected with dengue in southeast Asia, researchers at Imperial College London examined the antibodies produced by the patients’ immune systems. Antibodies are large proteins that recognize specific parts of foreign objects such as bacteria and viruses and signals to other parts of the immune system to attack the invader.

The researchers identified a new class of antibodies that is effective against all four strains of dengue virus. These antibodies could themselves be used to protect against or treat infections; or vaccines could be devised to stimulate the body to produce these antibodies.

The study, reported in the February issue of Nature Immunology, was led by Professor Gavin Screaton and Dr Juthathip Mongkolsapaya in the Department of Medicine at Imperial in collaboration with Dr Felix Rey and his colleagues at the Institut Pasteur in Paris. In a second paper, published in Nature, the researchers analyzed the antibodies’ structure, which is of crucial importance for vaccine development.

Professor Screaton said: “The incidence of dengue continues to increase despite attempts to control its spread. Outbreaks of dengue put huge stresses on the healthcare systems of endemic countries and a vaccine is desperately needed to check the disease. Current vaccine trials have shown some promise but do not fully protect from infection. The finding of this new class of antibodies points the way for a new approach to a dengue vaccine design which we are pursuing.”

Rather than binding to a single protein on the surface of the virus, these antibodies target a molecular bridge between two proteins. Although the four strains of dengue virus have variations in their surface proteins, the molecular bridge is the same, enabling the antibodies to neutralize all the different types.

A vaccine containing the bridge, or a closely similar molecule, could work by training the immune system to recognize and attack dengue viruses.